Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops
Before successful weight loss treatments such as Wegovy and Ozempic, the pharmaceutical path to treating obesity was strewn with failures
Read MoreBefore successful weight loss treatments such as Wegovy and Ozempic, the pharmaceutical path to treating obesity was strewn with failures
Read MoreThese are the stocks posting the largest moves in premarket trading. Source link
Read MorePfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug,
Read MoreShares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the
Read MoreThe Xi dinner was a hot ticket for CEOs of America's most prominent companies, and a chance to rub elbows
Read MoreThe stock market is enjoying its best week of 2023, but some names may have gotten ahead of themselves. Source
Read MoreHere are the most important news items that investors need to start their trading day. Source link
Read MoreMerck's revenue and earnings beat expectations, and it hiked its sales forecast while lowering its profit outlook. Source link
Read MoreHere are the biggest calls on Wall Street on Source link
Read More